John Bernard

741 total citations
8 papers, 472 citations indexed

About

John Bernard is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Hematology. According to data from OpenAlex, John Bernard has authored 8 papers receiving a total of 472 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Pulmonary and Respiratory Medicine, 3 papers in Radiology, Nuclear Medicine and Imaging and 3 papers in Hematology. Recurrent topics in John Bernard's work include Prostate Cancer Treatment and Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Multiple Myeloma Research and Treatments (2 papers). John Bernard is often cited by papers focused on Prostate Cancer Treatment and Research (4 papers), Radiopharmaceutical Chemistry and Applications (3 papers) and Multiple Myeloma Research and Treatments (2 papers). John Bernard collaborates with scholars based in France, United States and Spain. John Bernard's co-authors include Mustapha Chadjaa, Paul N. Mainwaring, Fred Saad, Orazio Caffo, Antoine Thiery-Vuillemin, Jacek Jassem, Daniel Castellano, Karim Fizazi, Lisa Sengeløv and Steinbjørn Hansen and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Endocrine Related Cancer.

In The Last Decade

John Bernard

8 papers receiving 466 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John Bernard France 5 363 135 135 129 90 8 472
Ayse Ӧzatılgan France 8 442 1.2× 176 1.3× 148 1.1× 172 1.3× 65 0.7× 21 495
Marie Hjälm-Eriksson Sweden 8 367 1.0× 113 0.8× 111 0.8× 83 0.6× 36 0.4× 17 455
Nahla Hasabou United States 9 245 0.7× 83 0.6× 88 0.7× 123 1.0× 115 1.3× 30 467
Alexis K. Smith United States 7 341 0.9× 145 1.1× 118 0.9× 122 0.9× 27 0.3× 10 513
David Forer United States 11 569 1.6× 137 1.0× 194 1.4× 258 2.0× 71 0.8× 23 634
R. Nevin Murray Canada 7 540 1.5× 203 1.5× 173 1.3× 242 1.9× 43 0.5× 10 651
Curtis Dunshee United States 11 424 1.2× 225 1.7× 130 1.0× 110 0.9× 26 0.3× 41 548
W D Figg United States 5 222 0.6× 99 0.7× 96 0.7× 28 0.2× 82 0.9× 6 357
Flavio Mavignier Cárcano Brazil 12 193 0.5× 89 0.7× 101 0.7× 49 0.4× 18 0.2× 34 418
Ines Figueiredo United Kingdom 11 356 1.0× 237 1.8× 232 1.7× 93 0.7× 18 0.2× 26 576

Countries citing papers authored by John Bernard

Since Specialization
Citations

This map shows the geographic impact of John Bernard's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Bernard with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Bernard more than expected).

Fields of papers citing papers by John Bernard

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John Bernard. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Bernard. The network helps show where John Bernard may publish in the future.

Co-authorship network of co-authors of John Bernard

This figure shows the co-authorship network connecting the top 25 collaborators of John Bernard. A scholar is included among the top collaborators of John Bernard based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John Bernard. John Bernard is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Brose, Marcia S., Jaume Capdevila, Rossella Elisei, et al.. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine Related Cancer. 31(8). 4 indexed citations
2.
Morland, Bruce, Tomáš Kepák, Sandro Dallorso, et al.. (2020). Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC). Bone Marrow Transplantation. 55(9). 1744–1753. 19 indexed citations
3.
Manley, Peter, Tanya Trippett, Amy Smith, et al.. (2018). A phase 1/2 dose‐finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system. Pediatric Blood & Cancer. 65(9). e27217–e27217. 12 indexed citations
4.
Oudard, Stéphane, Karim Fizazi, Lisa Sengeløv, et al.. (2017). Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial—FIRSTANA. Journal of Clinical Oncology. 35(28). 3189–3197. 239 indexed citations
5.
Eisenberger, Mario A., Anne-Claire Hardy-Bessard, Choung‐Soo Kim, et al.. (2017). Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA. Journal of Clinical Oncology. 35(28). 3198–3206. 163 indexed citations
6.
7.
Sartor, Oliver, Stéphane Oudard, Lisa Sengeløv, et al.. (2016). Cabazitaxel vs docetaxel in chemotherapy-naive (CN) patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm phase III study (FIRSTANA).. Journal of Clinical Oncology. 34(15_suppl). 5006–5006. 32 indexed citations
8.
Eymard, Jean‐Christophe & John Bernard. (2003). [Cell therapy and prostate cancer].. PubMed. 90(8-9). 734–43. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ayse Ӧzatılgan Breakdown of academic impact, for papers by Marie Hjälm-Eriksson Breakdown of academic impact, for papers by Nahla Hasabou Breakdown of academic impact, for papers by Alexis K. Smith Breakdown of academic impact, for papers by David Forer Breakdown of academic impact, for papers by R. Nevin Murray Breakdown of academic impact, for papers by Curtis Dunshee Breakdown of academic impact, for papers by W D Figg Breakdown of academic impact, for papers by Flavio Mavignier Cárcano Breakdown of academic impact, for papers by Ines Figueiredo
Rankless by CCL
2026